Cancer Research UK will repurpose an AstraZeneca asthma drug for kidney cancer

Cancer Research UK has struck a deal with AstraZeneca ($AZN) to repurpose an experimental therapy originally developed by the drug giant for asthma and study its ability to fight kidney cancer.

Renal cancer or kidney cancer is a disease that occurs when the kidney cells get malignant or cancerous. When this happens then the kidney cells are not under control and they develop into a tumor. The majority of cases of kidney cancer start in the tubules which are the lining of tiny tubes present in the kidney. This is the renal cell carcinoma.

Most of the cases of kidney cancers are detected before they spread to any other organ. If the cancer is caught early then it can also be treated successfully. However, at times, the tumour may grow very large before they get detected. Most cases of health issues and their treatment plans can be read about in this directory. You should however check this space if you want a clear and blemish free skin.

Kidneys are shaped like a bean and each has the same size as that of a fist. These lie in the lower abdomen region on either side of the spine. The kidney cleans the blood and removes waste from the body. It makes urine.

There are some factors that increase the risk of one getting kidney cancer. Kidney cancer risk is higher in those who are over 40 years of age.

Under the agreement, the nonprofit’s drug development office will carry out preclinical testing and early clinical trials of the compound, AZD2098. Cancer Research UK plans to begin enrolling up to 40 patients in an early phase study in 2015

AZD2098 targets a molecule called CCR4, which is found on immune cells and helps direct these cells to where they need to go. In kidney cancer, CCR4 is thought to drive immune cells toward the tumor cell. When this happens, the tumor causes the immune cells that are redirected toward it to become inactive or, in the worst case, aid the spread of cancer.

Frances Balkwill at Queen Mary University of London’s Barts Cancer Institute, with funding from Cancer Research UK, found that AZD2098 may be able to block this function by changing the immune cell environment around the cancer, instead stimulating those cells to attack the tumor.